A field comparison of the efficacy and tolerance of marbofloxacin in the treatment of bovine respiratory disease

Abstract

A multicentre, controlled, randomized and blinded trial was carried out in 180 ruminating calves with pyrexia and respiratory sign(s) on nine Belgian, British and French farms. All animals were sampled for pathogenic bacteria before treatment and at failure/relapse. Calves were injected with either marbofloxacin (M) solution [Marbocyl (Laboratoire Vétoquinol, Lure, France) 10%] at 2 mg/kg/24 h for 4 days intravenously on the first day then subcutaneously, or tilmicosin (T) solution (Micotil, Elanco Products Ltd, Basingstoke, Hants, UK) at 10 mg/kg as a single subcutaneous (s.c.) injection. The animals were examined clinically eight times up to day 28. The bacterial pathogens were found to be sensitive to marbofloxacin: for Pasteurella haemolytica the minimum inhibitory concentration (MIC)90 was 0.08 microg/mL and for P. multocida the MIC90 was 0.04 microg/mL. Cure rates at day 4 for group M and group T were 84 vs. 82%, respectively (P > or = 0.05). However, overall clinical score was significantly lower after 1 day in group M (P < 0.05). There was no difference in either relapse rate or average daily weight gain between groups. Marbofloxacin was found to be better tolerated than tilmicosin at the s.c. injection site (77.5 vs. 42.2% calves without local swelling, P=0.001) and was well tolerated when injected intravenously. Marbofloxacin was shown to have comparable but faster efficacy and better local tolerance than tilmicosin in the treatment of bovine respiratory disease (BRD).

Interaction between Marbofloxacin and Flunixin in Treatment of Pneumonia in Lambs

“…These results are agreed with Valle et al, [23] who stated that marbofloxacin was very active against bovine respiratory tract pathogen as Pasteurella multocida. Also, our results coincide with those obtained by Thomas et al, [4] they recorded that marbofloxacin has been approved for treatment of respiratory disease in cattle, pigs, dogs, and cats. Pneumonic lambs showed clinical signs as fever, bilateral nasal discharge, congested mucous membranes, moist cough, dyspnea and recombency.…”

“…Marbofloxacin is a 3 rd generation synthetic bactericidal drug belonging to fluoroquinolones acts by inhibition of DNA gyrase. It is effective against a wide range of Gr +ve & Gr-ve bacteria as pasteurella multocida [4]. It is used for treatment of respiratory and urinary diseases [5].…”

Pharmacokinetic and pharmacodynamic testing of marbofloxacin administered as a single injection for the treatment of bovine respiratory disease

“…As Marbocyl Ò 10% (Vétoquinol, Lure, France), marbofloxacin has been authorized in Europe since 1997 for the treatment of bovine infections at a daily dosage of 2 mg ⁄ kg for 3-5 days using various routes of administration. For this approved dosing regimen, PK ⁄ PD integration and PK ⁄ PD modelling using the two main PK ⁄ PD surrogate markers area under the curve (AUC) ⁄ minimum inhibitory concentration (MIC) ratio ‡125 h and C max ⁄ MIC ratio ‡10 (maximal concentration ⁄ minimum inhibitory concentration) correlated very well with clinical efficacy in the field (Thomas et al, 2001;Aliabadi & Lees, 2002;Sidhu et al, 2011).…”

Pharmacokinetic/pharmacodynamic relationship of marbofloxacin against Pasteurella multocida in a tissue‐cage model in yellow cattle

“…Marbofloxacin is a lipid-soluble organic acid which readily penetrates tissues to achieve concentrations commonly higher than those in plasma. It is licensed in many countries for use in cattle, pigs, dogs, horses and cats for the treatment for respiratory, urinary tract, soft tissue and dermatological infections (Cotard et al, 1995;Thomas et al, 1997Thomas et al, , 2000Thomas et al, , 2001Dossin et al, 1998). However, to our knowledge, there has not been a published pharmacokinetic study of marbofloxacin in yellow cattle which have ever been widely used primarily for draft animal in China, but now are being selected for meat production as well.…”